J&J said it plans to expand the early-stage technology from total and partial knee replacements into other orthopedic surgeries as part of its bid to create a new robot-assisted platform using “enabling technologies to personalize procedures, optimize surgery and bring value to customers and patients.”
“Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopedics platform, delivering value to patients, physicians and healthcare providers across the episode of care,” DePuy Synthes chairman Ciro Rӧmer said in prepared remarks. “The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction.”
Orthotaxy was founded by Stéphane Lavallée, a robotics entrepreneur, J&J said.
In addition to its in-house robotics program, Johnson & Johnson is in a joint venture with Alphabet‘s (NSDQ:GOOGL) Verily Life Sciences called Verb Surgical, which debuted its prototype early last year.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.